Clinical Trials Results - National Cancer Institute

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

In English \| En español
Search

NCI Home

Cancer Topics


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-15 of 15 for your search:

Drug:  palifermin
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 20050100, NCT00352703

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer

Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040122, NCT00393822

Phase III Randomized Study of Recombinant Human Keratinocyte Growth Factor in Reducing Therapy-Induced Oral Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-Dose Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation

Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0012064, AMGEN-KGF-20000162, FHCRC-1612.00, MSKCC-01065, NCI-G01-1961

Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer

Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20020402, NCT00101582

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer

Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040118, NCT00131638

Phase III Randomized Study of Palifermin for Reducing Oral Mucositis in Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx Undergoing Concurrent Radiotherapy and Chemotherapy

Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0435, RTOG 0435, NCT00360971

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma

Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 20050219, NCT00434161

Phase I/II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients with Hodgkin's Disease and Non-Hodgkin's Lymphoma Undergoing High Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation

Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Closed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-97112, AMGEN-KGF-960189, NCI-G97-1368

Phase I/II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy (Summary Last Modified 03/2000)

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Adult
Sponsor: NCI
Protocol IDs: RPCI-DS-97-33, AMGEN-KGF-970149-08, NCI-G98-1397

10.

Phase II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients with Hematologic Malignancies Undergoing Total Body Irradiation and High Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Support

Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: 18 to 65
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MSKCC-99029, AMGEN-KGF-980231-04, NCI-G99-1574, NCT00004061

11.

Phase II Randomized Study of Recombinant Human Keratinocyte Growth Factor for Oral Mucositis in Patients With Hematologic Malignancies Undergoing Radiotherapy and High Dose Chemotherapy Prior to Autologous Peripheral Blood Stem Cell Transplantation

Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 12 to 65
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-9812041, AMGEN-KGF-980231-03, NCI-G99-1609, NCT00004132

12.

Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase: Phase II
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20030185, NCT00094861

13.

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation

Phase: Phase II
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040213, NCT00189488

14.

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

Phase: Phase II
Type: Supportive care
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2004-0511, NCT00267046

15.

Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support

Phase: Phase I
Type: Supportive care
Status: Completed
Age: 18 to 76
Sponsor: Other
Protocol IDs: 20010182, NCT00070616

Select All on Page

Help with Results

A Service of the National Cancer Institute